The National Institute for Health and Care
Excellence (NICE) has today published its Final Appraisal Determination on
the use of guselkumab (Tremfya) for severe psoriasis in England and Wales.
Guselkumab (Tremfya) is recommended to treat severe
psoriasis, where people have not had adequate results from conventional
systemic treatments, or cannot take
Tremfya blocks the activity of interleukin 23 (IL-23), a
chemical ’messenger’ in the immune system that signals other cells to cause
inflammation. In people with psoriasis the immune system is overactive and
creates too much inflammation, which leads to the development of psoriasis
symptoms. By blocking IL-23, Tremfya aims to prevent some of that inflammation
from occurring, leading to an improvement in psoriasis for some people who take
it. There is currently one other biologic medication available that blocks
the activity of IL-23 available for people with severe psoriasis, called
UPDATE - 14th June 2018
NICE has now published final guidance on the use of guselkumab (Tremfya) in severe psoriasis. Please click here to read the final guidance, or click here for more information on Tremfya.